Close

Centrexion eyes the IPO to fund its phase 3 clinical trial

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The Ultimate Pain Relief Guide: Proven Tips to Manage Discomfort Naturally

Pain is something that we all go through somehow...

In its attempt to list on the NASDAQ, Centrexion Therapeutics has restarted the effort of going public yet again. The biotech company through the IPO hopes to find suitable investors that could help raise funds for a phase 3 program. Phase 3 involves testing of CNTX-4975, a synthetic form of molecule found in chili peppers, in patients who are suffering from moderate to severe pain related to osteoarthritis of the knee.

The company is yet to propose the terms for the IPO but wants to make sure that through this it raises enough money to see it through the delivery of data from the first phase 3 trial. The company also plans to use the funds raised by the IPO to complete phase 1 trials of CNTX-6016 and CNTX-6970. The fourth in line CNTX-0290 has been sold to Eli Lilly for a payout of $47.5 million upfront.

Latest stories